Revised outcome of Board Meeting and un-audited financial results for the quarter ended 30th september, 2025 for corretion of UDIN in Limited Review Report. It is to submit that except ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CDG Petchem filed revised unaudited results for Q2/H1 FY26 (ended 30 Sep 2025), originally submitted the same day with a UDIN error in the Limited Review Report. Revenue from operations crashed to ₹22.21 lakhs in Q2 FY26 vs ₹109.56 lakhs in Q2 FY25 (~80% YoY decline) and to ₹47.97 lakhs in H1 FY26 vs ₹373.59 lakhs in H1 FY25 (~87% decline). The company reported a Q2 profit of ₹13.82 lakhs, but this was entirely driven by ₹16.19 lakhs of interest from fixed deposits, not operations. The balance sheet shows a dramatic turnaround — equity shifted from negative ₹20.63 lakhs (March 2025) to ₹2,544.15 lakhs after a ₹2,603 lakh capital raise via shares and warrants, pushing cash to ₹2,623 lakhs. Alongside results, the Board accepted resignations of 3 Independent Directors, 2 Non-Executive Directors, the CFO and internal auditor, and appointed replacements including a new CFO and new internal auditor (HRB & Associates).
The core business is in severe revenue contraction and was loss-making at the operating level, which is a serious red flag for shareholders; however, the large equity infusion has rescued the balance sheet and bought runway. The sweeping Board and key managerial changes raise governance concerns and warrant close scrutiny of who is now controlling the company and how the fresh capital will be deployed.